Trade Editas Medicine - EDIT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.35 |
| Open | 2.33 |
| 1-Year Change | -76.95% |
| Day's Range | 2.33 - 2.51 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 2.35 | -0.07 | -2.89% | 2.42 | 2.44 | 2.28 |
| Nov 20, 2024 | 2.39 | -0.07 | -2.85% | 2.46 | 2.46 | 2.33 |
| Nov 19, 2024 | 2.46 | 0.00 | 0.00% | 2.46 | 2.53 | 2.45 |
| Nov 18, 2024 | 2.50 | -0.06 | -2.34% | 2.56 | 2.66 | 2.49 |
| Nov 15, 2024 | 2.64 | -0.12 | -4.35% | 2.76 | 2.78 | 2.57 |
| Nov 14, 2024 | 2.76 | -0.08 | -2.82% | 2.84 | 2.95 | 2.74 |
| Nov 13, 2024 | 2.94 | -0.16 | -5.16% | 3.10 | 3.18 | 2.93 |
| Nov 12, 2024 | 3.05 | -0.13 | -4.09% | 3.18 | 3.23 | 3.02 |
| Nov 11, 2024 | 3.27 | 0.10 | 3.15% | 3.17 | 3.35 | 3.13 |
| Nov 8, 2024 | 3.10 | -0.04 | -1.27% | 3.14 | 3.22 | 3.02 |
| Nov 7, 2024 | 3.15 | -0.10 | -3.08% | 3.25 | 3.28 | 3.09 |
| Nov 6, 2024 | 3.26 | 0.10 | 3.16% | 3.16 | 3.37 | 3.04 |
| Nov 5, 2024 | 3.09 | 0.29 | 10.36% | 2.80 | 3.14 | 2.73 |
| Nov 4, 2024 | 2.84 | -0.05 | -1.73% | 2.89 | 3.06 | 2.68 |
| Nov 1, 2024 | 2.88 | -0.04 | -1.37% | 2.92 | 3.00 | 2.88 |
| Oct 31, 2024 | 2.88 | -0.10 | -3.36% | 2.98 | 2.99 | 2.88 |
| Oct 30, 2024 | 3.00 | -0.05 | -1.64% | 3.05 | 3.13 | 2.98 |
| Oct 29, 2024 | 3.08 | -0.13 | -4.05% | 3.21 | 3.33 | 3.04 |
| Oct 28, 2024 | 3.24 | 0.05 | 1.57% | 3.19 | 3.29 | 3.17 |
| Oct 25, 2024 | 3.16 | 0.00 | 0.00% | 3.16 | 3.33 | 3.15 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Editas Medicine Company profile
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
11 Hurley St
CAMBRIDGE
MASSACHUSETTS 02141-2110
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com